Common name
|
B-Tg(mCd30l) MC38
|
Catalog number
|
322165
|
Aliases
|
CD153, Cd30l, CD30LG, Tnlg3a, Tnfsf8
|
Disease
|
Colon carcinoma
|
Organism
|
Mouse
|
Strain
|
C57BL/6
|
Tissue types
|
Colon
|
Tissue
|
Colon
|
Description
The exogenous promoter and mouse Cd30l coding sequence were inserted into the mouse genome randomly. Mouse Cd30l is highly expressed on the surface of B-Tg(mCd30l) MC38 cells.
Application
B-Tg(mCd30l) MC38 cells have the capability to establish tumors in vivo and can be used for efficacy studies.
Targeting strategy
Gene targeting strategy for B-Tg(mCd30l) MC38 cells. The exogenous promoter and mouse Cd30l coding sequence were inserted into the mouse genome randomly.
Protein expression analysis
Cd30l expression analysis in B-Tg(mCd30l) MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38 and B-Tg(mCd30l) MC38 cultures were stained with species-specific anti-Cd30l antibody. Mouse Cd30l was detected on the surface of B-Tg(mCd30l) MC38 cells but not wild-type MC38 cells. The 1-E03 clone of B-Tg(mCd30l) MC38 cells was used for in vivo experiments.
Tumor growth curve & Body weight changes
Subcutaneous homograft tumor growth of B-Tg(mCd30l) MC38 cells. B-Tg(mCd30l) MC38 cells (5x105) and wild-type MC38 cells (5x105) were subcutaneously implanted into C57BL/6N mice (female, 6-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-Tg(mCd30l) MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.
Protein expression analysis of tumor cells
B-Tg(mCd30l) MC38 cells were subcutaneously transplanted into C57BL/6N mice (n=5). At the end of the experiment, tumor cells were harvested and assessed for mouse Cd30l expression by flow cytometry. As shown, mouse Cd30l was highly expressed on the surface of tumor cells. Therefore, B-Tg(mCd30l) MC38 cells can be used for in vivo efficacy studies of novel Cd30l therapeutics.